StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Monday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

CHEK opened at $0.73 on Monday. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.45. The firm has a market capitalization of $4.27 million, a PE ratio of -0.24 and a beta of 0.19. The company’s 50-day moving average is $0.97 and its 200 day moving average is $1.14.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.